The European Commission has approved Beovu for the treatment of wet age-related macular degeneration, Novartis announced in a press release.
Beovu (brolucizumab) is the first anti-VEGF treatment approved by the EC to demonstrate superior resolution of retinal fluid vs. aflibercept, and it maintains wet AMD patients on a 3-month dosing interval after the loading phase, the release said.
“Currently, wet AMD patients, who are often older, can face significant challenges in managing their disease. We believe that Beovu, and its ability to resolve fluid, brings great therapeutic value that
Uncategorized